EUR 0.48
(4.46%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 1.98 Million EUR | 193.92% |
2022 | 674 Thousand EUR | -94.97% |
2021 | 13.39 Million EUR | 96.84% |
2020 | 6.8 Million EUR | -74.37% |
2019 | 26.55 Million EUR | -64.4% |
2018 | 74.6 Million EUR | 1310.26% |
2017 | 5.29 Million EUR | 7428.85% |
2016 | 70.26 Thousand EUR | 17.8% |
2015 | 59.65 Thousand EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | 0.0% |
2012 | - EUR | 0.0% |
2011 | - EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2023 FY | 1.98 Million EUR | 193.92% |
2023 Q4 | 1.02 Million EUR | 0.0% |
2023 Q2 | 955 Thousand EUR | 0.0% |
2022 FY | 674 Thousand EUR | -94.97% |
2022 Q4 | 591 Thousand EUR | 0.0% |
2022 Q2 | 83 Thousand EUR | 0.0% |
2021 FY | 13.39 Million EUR | 96.84% |
2021 Q2 | 13.27 Million EUR | 0.0% |
2021 Q4 | 123 Thousand EUR | 0.0% |
2020 Q2 | 6.37 Million EUR | 0.0% |
2020 FY | 6.8 Million EUR | -74.37% |
2020 Q4 | 434 Thousand EUR | 0.0% |
2019 FY | 26.55 Million EUR | -64.4% |
2019 Q1 | 6.63 Million EUR | -73.36% |
2019 Q2 | 23.16 Million EUR | 248.97% |
2019 Q4 | 3.38 Million EUR | 0.0% |
2018 FY | 74.6 Million EUR | 1310.26% |
2018 Q4 | 24.91 Million EUR | 0.0% |
2018 Q1 | 18.65 Million EUR | 252.58% |
2018 Q2 | 37.46 Million EUR | 100.86% |
2017 Q2 | 1.32 Million EUR | 0.0% |
2017 FY | 5.29 Million EUR | 7428.85% |
2017 Q4 | 5.29 Million EUR | 0.0% |
2017 Q1 | 1.32 Million EUR | 1782.21% |
2016 Q1 | 17.56 Thousand EUR | 82.03% |
2016 Q4 | 70.26 Thousand EUR | 0.0% |
2016 FY | 70.26 Thousand EUR | 17.8% |
2016 Q2 | 17.56 Thousand EUR | 0.0% |
2015 Q2 | 50 Thousand EUR | 235.3% |
2015 FY | 59.65 Thousand EUR | 0.0% |
2015 Q4 | 9650.00 EUR | -35.29% |
2015 Q3 | 14.91 Thousand EUR | -70.18% |
2015 Q1 | 14.91 Thousand EUR | 0.0% |
2014 Q4 | 14.91 Thousand EUR | 0.0% |
2014 Q3 | - EUR | 0.0% |
2014 Q2 | - EUR | 0.0% |
2014 Q1 | - EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2013 FY | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2013 Q2 | - EUR | 0.0% |
2013 Q3 | - EUR | 0.0% |
2013 Q1 | - EUR | 0.0% |
2012 Q3 | - EUR | 0.0% |
2012 FY | - EUR | 0.0% |
2012 Q1 | - EUR | 0.0% |
2012 Q2 | - EUR | 0.0% |
2012 Q4 | - EUR | 0.0% |
2011 Q2 | - EUR | 0.0% |
2011 FY | - EUR | 0.0% |
2011 Q1 | - EUR | 0.0% |
2011 Q4 | - EUR | 0.0% |
2011 Q3 | - EUR | 0.0% |
2010 Q4 | - EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
ABIONYX Pharma SA | 4.64 Million EUR | 57.306% |
ABIVAX Société Anonyme | 4.62 Million EUR | 57.13% |
Adocia SA | 2.15 Million EUR | 7.86% |
Aelis Farma SA | 9.05 Million EUR | 78.12% |
Biophytis S.A. | - EUR | -Infinity% |
Advicenne S.A. | 3.15 Million EUR | 37.131% |
genOway Société anonyme | 20.04 Million EUR | 90.118% |
IntegraGen SA | 12.53 Million EUR | 84.199% |
Medesis Pharma S.A. | 300.03 Thousand EUR | -560.259% |
Neovacs S.A. | 533.41 Thousand EUR | -271.383% |
NFL Biosciences SA | - EUR | -Infinity% |
Plant Advanced Technologies SA | 1.68 Million EUR | -17.81% |
Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -9907.072% |
Sensorion SA | 4.74 Million EUR | 58.234% |
Theranexus Société Anonyme | 296.33 Thousand EUR | -568.509% |
TME Pharma N.V. | 17 Thousand EUR | -11552.941% |
Valbiotis SA | 4.73 Million EUR | 58.145% |
TheraVet SA | 1.07 Million EUR | -83.757% |
Valerio Therapeutics Société anonyme | 1.8 Million EUR | -10.056% |
DBV Technologies S.A. | - EUR | -Infinity% |
Genfit S.A. | 28.56 Million EUR | 93.065% |
GeNeuro SA | - EUR | -Infinity% |
Innate Pharma S.A. | 51.9 Million EUR | 96.183% |
Inventiva S.A. | 17.47 Million EUR | 88.665% |
MaaT Pharma SA | 2.22 Million EUR | 11.086% |
MedinCell S.A. | 9.16 Million EUR | 78.373% |
Nanobiotix S.A. | 30.05 Million EUR | 93.409% |
OSE Immunotherapeutics SA | 2.22 Million EUR | 11.046% |
GenSight Biologics S.A. | 1.26 Million EUR | -56.354% |
Transgene SA | 1.18 Million EUR | -67.314% |
Valneva SE | 153.71 Million EUR | 98.711% |